Moody’s downgrades Senegal to Caa1 amid rising debt concerns
President and CEO of STERIS plc (NYSE:STE), Carestio Daniel A, sold 159 shares of the company’s ordinary shares at a price of $241.82 on October 6, 2025. The transaction, valued at $38,449, comes as the medical equipment company trades near its 52-week high of $253, with a market capitalization of $23.8 billion. According to InvestingPro analysis, STERIS maintains a GREAT financial health score, supported by strong cash flows and moderate debt levels.
Following the transaction, Carestio directly owns 51,096 ordinary shares of STERIS plc, 33,054 of which are restricted and will lapse between June 1, 2026, and June 5, 2028. The company has maintained dividend payments for 21 consecutive years, with a current dividend yield of 1.04% and impressive dividend growth of 21.15% over the last twelve months. For comprehensive insider trading analysis and 12 additional InvestingPro insights, explore STERIS’s Pro Research Report, part of the exclusive coverage available for 1,400+ top US stocks.
In other recent news, STERIS plc reported impressive financial results for the first quarter of 2025, exceeding both earnings and revenue expectations. The company’s earnings per share (EPS) reached $2.34, surpassing the forecast of $2.26, marking a 3.54% surprise. Revenue also outperformed projections, coming in at $1.39 billion compared to the expected $1.36 billion. These results highlight STERIS’s strong market position and operational effectiveness. The company’s robust performance has been well-received, reflecting positively on its future outlook. While the stock price saw a notable increase following the announcement, analysts have yet to provide updated ratings or projections. STERIS’s recent developments underscore its financial health and ability to exceed market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.